Palacio-Pastrana C, Chávez-Mondragón E, Soto-Gómez A, et al. - In this Phase III, multicenter, prospective, double-blind, clinical trial, researchers sought to compare the safety and effectiveness of difluprednate 0.05% (PRO-145) vs prednisolone acetate 1% (Prednefrin® SF), for management of postoperative inflammation and pain, after cataract surgery. Intent-to-treat population comprised 178 post-phacoemulsification individuals that were assigned to receive either PRO-145, or prednisolone. In total, 171 patient were randomized (1:1) and completed the study. There was a significant improvement in the AC cell count and flare in both groups by the final visit compared to day 1. In patients undergoing phacoemulsification, PRO-145 is as effective and safe as prednisolone acetate in treating postoperative inflammation and pain.